Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF and either PD-1 or PD-L1. “It’s exactly that,” said ...

She has since run the Boston Marathon to raise money for both the Museum of Science, and most recently, Dana-Farber Cancer Institute. This year, Johnson will run in the Boston Marathon again for ...

Nine patients with advanced kidney cancer who received an experimental vaccine tailored to their tumors’ specific mutations mounted an immune response to their disease and remained cancer-free ...

Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to develop and commercialize ICP-B02 as a cancer drug outside of China ...

About ICP-B02 (CM355) ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare and KeyMed. A Phase I/II clinical trial in China is ongoing to assess the safety, tolerability ...

Afterward, UFC CEO Dana White said Tsarukyan will need to re-earn his Makhachev rematch. "He's going back to the drawing board," White said. "I don't want anybody to ever fight hurt, ever.

UFC president Dana White slammed American fighter Bryce Mitchell after the 30-year-old made several antisemitic, homophobic and transphobic comments during a podcast in which he also praised Adolf ...